ABSTRACT
VASCULAR Pioglitazone Prevents the Endothelial Dysfunction Induced by Ischemia and

Reperfusion in Healthy Subjects
Yuka We used a human in vivo model of IR-induced endothelial dysfunction. First, a crossover study was performed to ascertain if pioglitazone administration prevents IR-induced impairment in endothelium-dependent vasodilatation. Second, to evaluate the involvement of COX-2 in its effect, we performed a single-arm study which ascertains if meloxicam, a COX-2 inhibitor, can diminish the protective effect of pioglitazone on IR-induced endothelial dysfunction.
METHODS
The present study was approved by the Ethics Committee of Okayama University
Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences (Okayama, Japan).
Written informed consent was obtained from all subjects before study commencement.
Protocol 1
Twenty healthy, nonsmoking volunteers (25-44 years; 19 men and one woman) were enrolled in a randomized, crossover study ( Figure 1A ). Participants were randomized to receive pioglitazone (30 mg/day) for 1 week or no treatment with a washout period of 1 month. On day 7, venous blood samples were drawn, and flow-mediated dilatation (FMD) in the distal brachial artery measured before and after IR. Any medications except for pioglitazone were not allowed during this protocol.
Protocol 2
In a separate single-arm study, 15 healthy volunteers received pioglitazone (30 mg/day) and the cyclooxygenase (COX)-2 inhibitor meloxicam (10 mg/day) for 1 week ( Figure 1B ).
On day 7, FMD was measured before and after IR. Any medications except for pioglitazone and meloxicam were not allowed during this protocol.
IR procedure
First, FMD measurement before IR was undertaken ( Figure 2 ). Then, a blood-pressure cuff placed on the proximal portion of the upper arm was inflated to suprasystolic pressure (50 mmHg above systolic blood pressure) for 15 min to induce ischemia. The cuff was then deflated and 15 min of reperfusion was allowed, resulting in a brief episode of IR. FMD after IR was measured again.
FMD measurement before and after IR
FMD of the distal brachial artery was assessed as described previously. (14) A 10-MHz linear array transducer probe (Unex Co. Ltd., Nagoya, Japan) was used to obtain longitudinal images of the brachial artery at baseline after rest in the supine position for ≥5 min. The diameter of the brachial artery was measured from clear anterior and posterior interfaces. A blood-pressure cuff at the right forearm was inflated to suprasystolic blood pressure for 5 min.
Measurements of the diameter of the brachial artery were made continuously until ≥2 min after release of the blood-pressure cuff. FMD was expressed as percentage dilatation from baseline diameter to maximum diameter (%FMD). To quantify inter-and intra-observer reproducibility, the baseline diameter of the brachial artery and FMD were measured by three individuals. Inter-and intra-observer coefficients were high (r>0.90).
Tests carried out on blood samples
In the protocol 1, the following parameters were measured from blood samples at day 7: Wuhan, China). Intra-and inter-assay coefficients of variation were <10% and <12%, respectively. The plasma level of ADMA was measured with an ELISA kit (ALPCO Diagnostics, Salem, MA, USA). Intra-and inter-assay coefficients of variation were <8% and 9%, respectively. Other markers were measured at SRL Co., Ltd. (Tokyo, Japan).
Statistical analysis
Estimates of sample size for the present study assumed 1 − β = 0.8 and a two-sided α of 0.05, and were made based on previous studies. (7, 8, 15) We assumed that IR decreased FMD from 8% to 2% with a standard deviation of 3%. Calculations of sample size suggested that detection of 50% prevention of this impairment by pioglitazone would require a sample size of 10 subjects in each crossover group. comparisons were made with a paired t-test. In protocol 1, the interaction between IR and the randomization group was studied by two-way ANOVA. Post hoc comparisons were made using the Bonferroni correction. P<0.05 was set as the threshold for significance. All analyses were carried out using SPSS v17.0 (SPSS, Chicago, IL, USA).
RESULTS
Pre-IR values of the diameter of the brachial artery and reactive hyperemia were similar in the control group and pioglitazone group in protocol 1, and similar between subjects in protocol 1 and protocol 2 ( Table 1) .
Protocol 1
Protocol 1 was a crossover study ( Figure 1) . Table 2 showed patients' characteristics and biochemical parameters one week after administration. The serum level of ecSOD was higher after 1 week of pioglitazone administration than in the control. However, the lipid profile and levels of glucose, insulin, soluble VCAM-1, and ADMA were similar after pioglitazone administration and in the control (Table 2) .
No carryover and no period effects were observed for FMD in statistical terms. In the control group and pioglitazone group, the diameter of the brachial artery after IR was slightly greater than that before IR (both P<0.05), but peak reactive hyperemia was similar before and after IR (Table 1) . FMD was lower after IR than before IR after 1 week in the control group 
DISCUSSION
The present study demonstrated, for the first time in humans, that pioglitazone protects against IR-induced endothelial dysfunction at a conduit artery. This effect is independent of the COX-2 pathway and seems to be mediated by activation of an anti-oxidative stress mechanism.
Our results support animal studies that showed pioglitazone can reduce reperfusion injury (11, 17) and infarct size in the myocardium. Taken together with our data, those results suggest that pioglitazone is a beneficial drug for the prevention of cardiovascular events in T2DM.
Our study had limitations. First, data were obtained from the blood circulation in the forearms of healthy volunteers, so potential differences between forearm circulation and coronary circulation, as well as between healthy and diabetic individuals, need to be considered. Second, even though protocol 1 had a cross-sectional design, baseline data in individual groups were not available. Statistical analyses showed no carryover effects or period effects between the two treatment periods with regard to FMD values, but we cannot exclude the possibility they influenced the results. Third, this study included only one woman, so the observed effects may not be applicable to women.
Conclusion
We demonstrated that pioglitazone administration could provide potent endothelial protection via an anti-oxidative stress effect. These findings represent the first human 
